Literature DB >> 1401906

Interference with cyclophosphamide-induced skin allograft tolerance by cyclosporin A.

K Nomoto1, M Eto, K Yanaga, Y Nishimura, T Maeda, K Nomoto1.   

Abstract

In a murine strain combination identical in H-2 Ag but disparate in minor histocompatibility (H) Ag consisting of C3H/He (C3H; H-2k, Mls-1b) mice as recipients and AKR/J (AKR; H-2k, Mls-1a) mice as donors, a permanent skin allograft tolerance can be achieved by the cyclophosphamide (CP)-induced tolerance system that consists of i.v. injection of donor spleen cells (day -2) and i.p. injection of CP 2 days later (day 0). Such permanent take of allografts in CP-induced tolerant mice was interfered with by intramuscular injection of cyclosporin A (CsA) from day -5 to day -1 and their grafts were rejected by 21 days after grafting. Mls-1a-reactive CD4+V beta 6+ T cells in the periphery, as the indicator to follow the kinetics of donor-reactive T cells, increased on day 0 and day 3 in the C3H mice treated with AKR spleen cells alone, whereas they disappeared rapidly from day 0 to day 3 in CP-induced tolerant mice. When CsA capable of interfering with IL-2 production and T cell proliferation was administered before CP treatment in CP-induced tolerance system, the number of CD4+V beta 6+ T cells in periphery did not increase on day 0 and 3, but increased on day 7 in contrast to the decreased number of those in CP-induced tolerant mice. On day 7, MLR against donor cells was decreased in CP-induced tolerant mice, but maintained in CsA-interfered tolerant mice. These result may indicate that the destruction of donor-Ag-stimulated, proliferating T cells by CP is interfered with by CsA, probably because CsA inhibits the proliferation of donor-reactive T cells at the time of CP treatment. Furthermore, these results also implicate that the protocol for immunosuppression with CsA and antimetabolites has to be designed carefully in clinical transplantation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1401906

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

Review 1.  T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor.

Authors:  A Bashey; S R Solomon
Journal:  Bone Marrow Transplant       Date:  2014-05-19       Impact factor: 5.483

2.  Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation.

Authors:  Mi Kwon; Rebeca Bailén; María Jesús Pascual-Cascón; Ana Isabel Gallardo-Morillo; Abel García Sola; Pascual Balsalobre; Laura Solán; Nieves Dorado; Cristina Muñoz; David Serrano; Carolina Martínez-Laperche; Ismael Buño; Javier Anguita; José Luis Díez-Martin
Journal:  Blood Adv       Date:  2019-11-12

Review 3.  Contemporary haploidentical stem cell transplant strategies in children with hematological malignancies.

Authors:  Ravi M Shah
Journal:  Bone Marrow Transplant       Date:  2021-03-05       Impact factor: 5.483

4.  Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide.

Authors:  Ashley T Munchel; Yvette L Kasamon; Ephraim J Fuchs
Journal:  Best Pract Res Clin Haematol       Date:  2011-07-13       Impact factor: 3.020

Review 5.  Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation.

Authors:  Leo Luznik; Paul V O'Donnell; Ephraim J Fuchs
Journal:  Semin Oncol       Date:  2012-12       Impact factor: 4.929

6.  Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases.

Authors:  R A Brodsky; L Luznik; J Bolaños-Meade; M S Leffell; R J Jones; E J Fuchs
Journal:  Bone Marrow Transplant       Date:  2008-07-14       Impact factor: 5.483

7.  HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.

Authors:  Leo Luznik; Paul V O'Donnell; Heather J Symons; Allen R Chen; M Susan Leffell; Marianna Zahurak; Ted A Gooley; Steve Piantadosi; Michele Kaup; Richard F Ambinder; Carol Ann Huff; William Matsui; Javier Bolaños-Meade; Ivan Borrello; Jonathan D Powell; Elizabeth Harrington; Sandy Warnock; Mary Flowers; Robert A Brodsky; Brenda M Sandmaier; Rainer F Storb; Richard J Jones; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2008-06       Impact factor: 5.742

8.  Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis.

Authors:  Chitra Krishnan; Adam I Kaplin; Robert A Brodsky; Daniel B Drachman; Richard J Jones; Dzung L Pham; Nancy D Richert; Carlos A Pardo; David M Yousem; Edward Hammond; Megan Quigg; Carrilin Trecker; Justin C McArthur; Avindra Nath; Benjamin M Greenberg; Peter A Calabresi; Douglas A Kerr
Journal:  Arch Neurol       Date:  2008-06-09

Review 9.  Modern approaches to HLA-haploidentical blood or marrow transplantation.

Authors:  Christopher G Kanakry; Ephraim J Fuchs; Leo Luznik
Journal:  Nat Rev Clin Oncol       Date:  2015-08-25       Impact factor: 66.675

Review 10.  High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation.

Authors:  Leo Luznik; Ephraim J Fuchs
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.